Features | Partner Sites | Information | LinkXpress
Sign In
BioConferenceLive
GLOBETECH PUBLISHING
JIB

Prospective Antidementia Drug Improves Brain Function

By BiotechDaily International staff writers
Posted on 15 Oct 2012
A new antidementia drug candidate has been found to be highly active in creating new neuronal connections and improving the cognitive function of rats with Alzheimer’s-like mental impairment.

Researchers at Washington State University (WSU; Pullman, WA, USA) have developed a new compound, named Dihexa, designed to repair damage that has already occurred and thereby recover lost brain function. This is a significant departure from current treatments for diseases such as Alzheimer’s, treatments that only slow the process of cell death or inhibit the neurotransmitter cholinesterase. Also, the Pharmaceutical Research and Manufacturers of America (PhRMA) reported that only 3 of 104 possible treatments have been approved in the past 13 years, a 34 to 1 ratio of setbacks to successes.

Joe Harding, professor at the WSU College of Veterinary Medicine, Jay Wright, professor at the WSU College of Arts and Sciences, and other WSU colleagues, reported their findings on October 10, 2012, in the early online section of the Journal of Pharmacology and Experimental Therapeutics. Prof. Harding designed a smaller version of the peptide angiotensin IV. Unlike the original peptide and early candidate molecules based on it, the new analog, Dihexa, was found to be both stable and able to cross the blood-brain barrier. It can also move from the gut into the blood and so could be taken orally in pill form.

The WSU team tested Dihexa on several dozen rats treated with scopolamine. Typically, a rat treated with scopolamine will not learn the location of a submerged platform in a water tank, orienting with cues outside the tank. After receiving Dihexa, all rats learned the task whether receiving the drug orally, by injection, or directly into the brain. Similar results were observed where a smaller group of old rats performed like young rats after treatment; however, while these results were statistically valid, studies with larger test groups will be needed to check the finding.

The "gold standard” compound for creating neuronal connections is brain-derived neurotrophic factor (BDNF). In bench assays using living nerve cells to monitor new neuronal connections, Dihexa was seven orders of magnitude more powerful than BDNF, which itself has yet to be effectively developed for therapeutic use. "We quickly found out that this molecule was [very highly] active,” said Prof. Harding. These results further suggest that Dihexa or molecules like it may also have applications for other neurodegenerative diseases or brain traumas where neuronal connections are lost. Development of Dihexa for human use will begin after safety testing and US Food and Drug Administration approval is obtained for clinical trials.

Related Links:

Washington State University




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel

Precise Ion Irradiation Dosing Method Developed for Cancer Therapy

Scientists are employing nuclear physics principles to provide more effective approaches to radiotherapy treatment for cancer patients. Radiation therapy using heavy ions is best suitable for cancer patients with tumors that are difficult to access, such as in the brain. These particles scarcely damage the penetrated... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.